HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study

BACKGROUND: There is accumulating evidence support human epidermal growth factor receptor 2 (HER2)-low as a biologically distinct subtype of breast cancer. The present study was conducted to explore whether HER2-low expression will affect the clinical efficacy of cyclin-dependent kinase (CDK) 4/6 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yingbo, Luo, Zhifen, Yu, Yang, Chen, Qi, He, Yaning, Liu, Chaojun, Nie, Bing, Zhu, Fangyuan, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434209/
https://www.ncbi.nlm.nih.gov/pubmed/36060981
http://dx.doi.org/10.3389/fendo.2022.1000704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434209/
https://www.ncbi.nlm.nih.gov/pubmed/36060981
http://dx.doi.org/10.3389/fendo.2022.1000704

Ejemplares similares